Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)

Pesatori, Angela Cecilia; Carugno, Michele; Consonni, Dario; Hung, Rayjean J.; Papadoupolos, A.; Landi, Maria Teresa; Brenner, Hermann; Müller, Heiko; Harris, Curtis C.; Duell, Eric J.; Andrew, Angeline S.; McLaughlin, John; Schwartz, Ann G.; Wenzlaff, Angela S.; Stücker, Isabelle

doi:10.1038/bjc.2013.506

Cited by 55 publications

(53 citation statements)

References 49 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies hypothesized that the association could be explained by long-term use of hormone replacement therapy prescribed to oophorectomized women 22, 44 . However, this explanation seems to be unlikely, as a previously published ILCCO pooled study demonstrated a protective effect of exogenous hormones, either oral contraceptives or hormone replacement therapy 45 .…”

Section: Discussionmentioning

confidence: 96%

Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium

Khedher

Neri

Papadopoulos

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Many clinical features of lung cancer are different in women and men. Sex steroid hormones exert effects in non-reproductive organs, such as the lungs. The association between menstrual and childbearing factors and the risk of lung cancer among women is still debated. We performed a pooled analysis of eight studies contributing to the International Lung Cancer Consortium (ILCCO; 4,386 cases and 4,177 controls). Pooled associations between menstrual or reproductive factors and lung cancer were estimated using multivariable unconditional logistic regression. Subgroup analyses were done for menopause status, smoking habits and histology. We found no strong support for an association of age at menarche and at menopause with lung cancer, but peri/postmenopausal women were at higher risk compared to premenopausal (OR 1.47, 95% CI 1.11–1.93). Premenopausal women showed increased risks associated with parity (OR 1.74, 95% CI 1.03–2.93) and number of children (OR 2.88 95% CI 1.21–6.93 for more than 3 children; P for trend 0.01) and decreased with breastfeeding (OR 0.54, 95% CI 0.30–0.98). In contrast, peri/postmenopausal subjects had ORs around unity for the same exposures. No major effect modification was exerted by smoking status or cancer histology. Menstrual and reproductive factors may play a role in the genesis of lung cancer, yet the mechanisms are unclear, and smoking remains the most important modifiable risk factor. More investigations in large well-designed studies are needed to confirm these findings and to clarify the underlying mechanisms of gender differences in lung cancer risk.

show abstract

Section: Discussionmentioning

confidence: 96%

Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium

Khedher

Neri

Papadopoulos

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Our data also suggested that women with previous cancers had a higher risk for subsequent NSCLC than men. The effect of hormone exposure on lung cancer risk among women is not well defined but may be a contributing factor in the elevated risk of second primary lung cancer in women with previous malignancy, especially breast cancer 29 .…”

Section: Discussionmentioning

confidence: 99%

Non–Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?

Nelson

Kim

et al. 2017

Clinical Lung Cancer

View full text Add to dashboard Cite

Background Patients with prior malignancies may be at increased risk for non-small cell lung cancer (NSCLC). However, the extent of risk is unknown for many cancer types and it is unclear who may benefit from screening. Methods The Surveillance, Epidemiology and End Results dataset from 1992-2012 was used to identify patients with prior malignancies who were diagnosed with NSCLC ≥6 months after their initial cancer. Standardized incidence ratios (SIR) for NSCLC were calculated as a ratio of observed to expected cases adjusted by person-years at risk. Cancers with SIR >1.0 had higher risk for NSCLC than expected. Analyses were stratified by sex, radiation, and histology. Results Among cancer survivors, 32,058 developed NSCLC. Smoking-related (lung, head and neck, bladder) and hematologic malignancies regardless of prior radiation therapy had the highest SIR for NSCLC (range 1.97-4.88). Prior colorectal and renal cancer survivors also had increased SIR for NSCLC (1.16 and 1.21, respectively). Women with previous pancreatic cancer treated with radiation, breast cancer with or without radiation, and those with thyroid cancer demonstrated higher SIR for lung adenocarcinoma. Men with prior irradiated prostate cancer also had elevated SIR (1.08, CI 1.01-1.15) for lung adenocarcinoma. Patients with melanoma, prostate or uterine cancer had lower SIR for NSCLC than expected. Conclusions Smoking-related malignancies had the highest risk for NSCLC. Radiation conferred elevated risk for NSCLC for certain cancers. Melanoma, prostate, uterine cancer survivors were at low risk for NSCLC. These results may help identify high-risk screening candidates in the growing population of cancer survivors.

show abstract

“…Tamoxifen is considered to exhibit an important antitumor effect by reducing the proportion of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 (31). A multicenter study conducted by the International Lung Cancer Consortium (32) revealed that oral contraceptives, accepted hormone replacement therapy or a combination of estrogen and progesterone had been demonstrated to reduce the risk of lung cancer. In recent years, endocrine agents have gradually been used in the treatment of NSCLC.…”

Section: Overall Survival -------------------------------------------mentioning

confidence: 99%

Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis

Luo

Wang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract.The present study aimed to analyze the clinical characteristics and prognosis-related factors of non-small cell lung cancer (NSCLC) patients with bone metastases at the time of diagnosis. A total of 46 NSCLC patients with skeletal metastases at the time of diagnosis from Anhui Provincial Hospital and Anhui Provincial Cancer Hospital Affiliated to Anhui Medical University (Hefei, China) between February 2010 and February 2012 were investigated retrospectively. The median age was 58 years, with a range of 40-80 years, the ratio of males and females was 2:1, and adenocarcinoma and squamous cell carcinoma accounted for 71.7 and 28.3% of cases, respectively. Furthermore, 84.8% of patients exhibited multiple skeletal metastases at more than two sites and 54.3% of patients experienced skeletal-related events at the time of diagnosis. The median overall survival (OS) time of the patients was 237 days, and Kaplan-Meier analysis demonstrated that patients with adenocarcinoma (P=0.002), single bone metastases (P=0.023), an Eastern Cooperative Oncology Group performance status of 0-1 (P<0.001) or positive expression of estrogen receptor (ER)-β (P=0.039) exhibited significantly longer survival times. Furthermore, multivariate analysis identified the following independent predictors of OS: Tumor subtype (P=0.022), the number of bone metastases (P=0.016) and an ER-β-positive tumor (P=0.035). In the cohort of NSCLC patients with bone metastases at the time of diagnosis, adenocarcinoma and multiple skeletal metastases were most common.

show abstract

Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)

Cited by 55 publications

References 49 publications

Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium

Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium

Non–Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?

Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis

Contact Info

Product

Resources

About